Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome.
A dose of 50 mg of acarbose was administered with a standard breakfast to 13 subjects with dumping syndrome. Significant attenuation of hyperglycaemia (p less than 0.01) was observed, and rises in plasma gastric inhibitory polypeptide, insulin and enteroglycagon were reduced (p less than 0.05). Plasma levels of neurotensin, vasoactive intestinal polypeptide and somatostatin were not affected. Dumping score was reduced, but this did not achieve statistical significance. In a longer-term study, 9 patients took acarbose, 50 mg t.i.d., for 1 month. No significant reduction in the number or severity of dumping attacks was observed, but a majority expressed a preference for the drug and some individuals experienced a marked improvement of symptoms.
D020909:Acarbose; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D004311:Double-Blind Method; D004377:Dumping Syndrome / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005934:Glucagon / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009496:Neurotensin / Q000097:blood; D009844:Oligosaccharides / Q000494:pharmacology*; D010191:Pancreatic Polypeptide / Q000097:blood; D011863:Radioimmunoassay; D014312:Trisaccharides / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D009844:Oligosaccharides; D014312:Trisaccharides; D009496:Neurotensin; D005749:Gastric Inhibitory Polypeptide; D010191:Pancreatic Polypeptide; D005934:Glucagon; D020909:Acarbose